Literature DB >> 30338465

Large variation in ESBL-producing Escherichia coli carriers in six European countries including Russia.

Sofia Ny1,2, Roman Kozlov3, Uga Dumpis4, Petra Edquist5, Kirsi Gröndahl-Yli-Hannuksela6, Anna-Maria Kling5, Danuta O Lis7, Christoph Lübbert8, Monika Pomorska-Wesołowska7, Ivan Palagin3, Aija Vilde4, Jaana Vuopio6, Jan Walter9, Karin Tegmark Wisell5.   

Abstract

We investigated the faecal carriage prevalence of extended-spectrum β-lactamase production in Escherichia coli (EP-EC) and/or Klebsiella pneumoniae (EP-KP) and risk factors associated with carriage among adult study subjects in Finland, Germany, Latvia, Poland, Russia and Sweden (partner countries). The aim was to get indicative data on the prevalence of ESBL-carriage in specific populations in the region. Faecal samples were collected from four study populations and screened on ChromID-ESBL and ChromID-OXA-48 plates. Positive isolates were further characterised phenotypically. Our results show a large variation in carrier prevalence ranging from 1.6% in Latvia to 23.2% in Russia for EP-EC. For the other partner countries, the prevalence of EP-EC were in increasing numbers, 2.3% for Germany, 4.7% for Finland, 6.6% for Sweden, 8.0% for Poland and 8.1% for all partner countries in total. Carriers of EP-KP were identified only in Finland, Russia and Sweden, and the prevalence was < 2% in each of these countries. No carriers of carbapenemase-producing isolates were identified. This is the first study reporting prevalence of carriers (excluding traveller studies) for Finland, Latvia, Poland and Russia. It contributes with important information regarding the prevalence of EP-EC and EP-KP carriage in regions where studies on carriers are limited.

Entities:  

Keywords:  Antibiotic resistance; Asymptomatic carriage; E. coli; ESBL; K. pneumoniae Europe and Russia

Mesh:

Substances:

Year:  2018        PMID: 30338465     DOI: 10.1007/s10096-018-3382-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study.

Authors:  Maris S Arcilla; Jarne M van Hattem; Manon R Haverkate; Martin C J Bootsma; Perry J J van Genderen; Abraham Goorhuis; Martin P Grobusch; Astrid M Oude Lashof; Nicky Molhoek; Constance Schultsz; Ellen E Stobberingh; Henri A Verbrugh; Menno D de Jong; Damian C Melles; John Penders
Journal:  Lancet Infect Dis       Date:  2016-10-14       Impact factor: 25.071

2.  Community carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study.

Authors:  Sofia Ny; Sonja Löfmark; Stefan Börjesson; Stina Englund; Maj Ringman; Jakob Bergström; Pontus Nauclér; Christian G Giske; Sara Byfors
Journal:  J Antimicrob Chemother       Date:  2016-10-24       Impact factor: 5.790

3.  Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany.

Authors:  Christoph Lübbert; Laurentia Straube; Claudia Stein; Oliwia Makarewicz; Stefan Schubert; Joachim Mössner; Mathias W Pletz; Arne C Rodloff
Journal:  Int J Med Microbiol       Date:  2014-12-09       Impact factor: 3.473

Review 4.  Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M.

Authors:  Paul-Louis Woerther; Charles Burdet; Elisabeth Chachaty; Antoine Andremont
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

5.  Extended-spectrum β-lactamase-producing Escherichia coli from retail chicken meat and humans: comparison of strains, plasmids, resistance genes, and virulence factors.

Authors:  Jan A J W Kluytmans; Ilse T M A Overdevest; Ina Willemsen; Marjolein F Q Kluytmans-van den Bergh; Kim van der Zwaluw; Max Heck; Martine Rijnsburger; Christina M J E Vandenbroucke-Grauls; Paul H M Savelkoul; Brian D Johnston; David Gordon; James R Johnson
Journal:  Clin Infect Dis       Date:  2012-12-14       Impact factor: 9.079

6.  Prevalence and molecular epidemiology of CTX-M extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals.

Authors:  M Edelstein; M Pimkin; I Palagin; I Edelstein; L Stratchounski
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

7.  Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia.

Authors:  Stefanie Van Aken; Nathalie Lund; Jonas Ahl; Inga Odenholt; Johan Tham
Journal:  Scand J Infect Dis       Date:  2014-09-08

8.  Occurrence of extended-spectrum beta-lactamases among Escherichia coli isolates from hospitalized and healthy children.

Authors:  R Franiczek; B Sobieszczańska; M Grabowski; K Mowszet; T Pytrus
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

9.  Antimicrobials increase travelers' risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae.

Authors:  Anu Kantele; Tinja Lääveri; Sointu Mero; Katri Vilkman; Sari H Pakkanen; Jukka Ollgren; Jenni Antikainen; Juha Kirveskari
Journal:  Clin Infect Dis       Date:  2015-01-21       Impact factor: 9.079

10.  Clonal Diversity of ESBL-Producing Escherichia coli Isolated from Environmental, Human and Food Samples.

Authors:  Elena Ojer-Usoz; David González; Ana Isabel Vitas
Journal:  Int J Environ Res Public Health       Date:  2017-06-23       Impact factor: 3.390

View more
  7 in total

1.  A multidrug-resistant microorganism infection risk prediction model: development and validation in an emergency medicine population.

Authors:  Juan González Del Castillo; Agustín Julián-Jiménez; Julio Javier Gamazo-Del Rio; Eric Jorge García-Lamberechts; Ferrán Llopis-Roca; Josep María Guardiola Tey; Mikel Martínez-Ortiz de Zarate; Carmen Navarro Bustos; Pascual Piñera Salmerón; Jesús Álvarez-Manzanares; María Del Mar Ortega Romero; Martin Ruiz Grinspan; Susana García Gutiérrez; Francisco Javier Martín-Sánchez; Francisco Javier Candel González
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-13       Impact factor: 3.267

2.  European hospitals as source of multidrug-resistant bacteria: analysis of travellers screened in Finland after hospitalization abroad.

Authors:  Mikael Kajova; Tamim Khawaja; Anu Kantele
Journal:  J Travel Med       Date:  2022-07-14       Impact factor: 39.194

3.  Comparative distribution of extended-spectrum beta-lactamase-producing Escherichia coli from urine infections and environmental waters.

Authors:  Anna Fagerström; Paula Mölling; Faisal Ahmad Khan; Martin Sundqvist; Jana Jass; Bo Söderquist
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

4.  Characteristics of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae and Contact to Animals in Estonia.

Authors:  Kaidi Telling; Age Brauer; Mailis Laht; Piret Kalmus; Karolin Toompere; Veljo Kisand; Matti Maimets; Maido Remm; Tanel Tenson; Irja Lutsar
Journal:  Microorganisms       Date:  2020-07-27

5.  Antimicrobial Resistance in Enterobacterales Bacilli Isolated from Bloodstream Infection in Surgical Patients of Polish Hospitals.

Authors:  M Kłos; M Pomorska-Wesołowska; D Romaniszyn; J Wójkowska-Mach; A Chmielarczyk
Journal:  Int J Microbiol       Date:  2021-01-16

6.  Prevalence of multidrug-resistant and extended-spectrum beta-lactamase producing Gram-negative isolates from clinical samples in a tertiary care hospital of Nepal.

Authors:  Aryatara Shilpakar; Mehraj Ansari; Kul Raj Rai; Ganesh Rai; Shiba Kumar Rai
Journal:  Trop Med Health       Date:  2021-03-11

7.  Low colonization rates with Multidrug-resistant Gram-negative bacteria in a German hospital-affiliated hemodialysis center.

Authors:  Ralph Wendt; Olaf Nickel; Almut Botsch; Margareta Lindner; Angela Bethge; Kathrin Marx; Bernhard R Ruf; Joachim Beige; Christoph Lübbert
Journal:  PLoS One       Date:  2020-10-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.